Molecular Cancer · 2006 · 184 citations · 30 references
MedicineOncologyPharmacologyCancer PharmacologyCell DivisionChemotherapyCell Cycle ControlCell Cycle PharmacologyCell Cycle SignalingCyclin-dependent KinasesMitotic InhibitorsPancreatic CancerCancer Cell Proliferation InhibitionCell Cycle InhibitionCell Cycle InhibitorsCyclin RegulationDna Synthesis InhibitionG2-m Transition ControlG2/m TransitionG2/m Transition Regulation
BACKGROUND: Many chemotherapeutic agents have been used to treat pancreatic cancer without success. Apigenin, a naturally occurring flavonoid, has been shown to inhibit growth in some cancer cell lines but has not been studied in pancreatic cancer. We hypothesized that apigenin would inhibit pancreatic cancer cell growth in vitro. RESULTS: Apigenin caused both time- and concentration-dependent inhibition of DNA synthesis and cell proliferation in four pancreatic cancer cell lines. Apigenin induced G2/M phase cell cycle arrest. Apigenin reduced levels of cyclin A, cyclin B, phosphorylated forms of cdc2 and cdc25, which are all proteins required for G2/M transition. CONCLUSION: Apigenin inhibits growth of pancreatic cancer cells through suppression of cyclin B-associated cdc2 activity and G2/M arrest, and may be a valuable drug for the treatment or prevention of pancreatic cancer.
30
Cyclin A is required at two points in the human cell cycle.
Michele Pagano, Rainer Pepperkok, Fulvia Verde et al. · The EMBO Journal · 1992 · 1.4K citations · Full text
Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis.
T. Fotsis, Michael S. Pepper, Stephen Breit et al. · PubMed · 1997 · 536 citations
Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential
Sara Caltagirone, Cosmo Rossi, Andreina Poggi et al. · International Journal of Cancer · 2000 · 438 citations · Full text
Medicine, Oncology, Pharmacology +13